Patent Cliff

Lilly says 2014 will not be "trough year"

Lilly says 2014 will not be "trough year"

By

Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.

Patent cliff a drag on 2012 health spend

Patent cliff a drag on 2012 health spend

By

Generics accounted for almost 75% of dispensed drugs in 2012, according to CMS researchers.

2014 shaping up to be bridge year for Lilly

2014 shaping up to be bridge year for Lilly

By

The company's guidance aligns with expectations that 2014 will be a nail-biter.

Merck seeks way to stem sales slide

Merck seeks way to stem sales slide

By

The company says it is moving its Januvia sales pitch from defending market share to expanding it.

Passing Plavix shadow, BMS sees sales bump

Passing Plavix shadow, BMS sees sales bump

By

BMS is showing signs of emerging from the cliff, but doubt lingers on Eliquis's slow launch in a post-Plavix marketplace.

Study shows swift move from brand to generic drugs

Study shows swift move from brand to generic drugs

By

Researchers say it's not just payers supporting the switch, and all ages appear to be brand agnostic.

Teva trimming 10% of staff ahead of MS drug expiry

Teva trimming 10% of staff ahead of MS drug expiry

By

The generics giant said it will lay off about 5,000 employees as it braces for the expiry of one of its specialty brands.

Teva's generic Advair may sit 'til 2018

The generics maker says it may take five years for its iteration of the GSK asthma/COPD brand to hit the market.

Sanofi expects Q4 growth: CEO

The CEO says Sanofi's patent-loss turnaround is coming.

Lilly primes investors for possible cuts

Lilly primes investors for possible cuts

By

Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.

Advisory panel backs GSK drug for COPD

By

The advisory panel endorsed the treatment with an 11-2 vote.

Business briefs: GSK, Roche, Biogen Idec, Forest

FDA draft guidance for generic Advair hits GSK's stock; US looks into GSK's China conduct; Roche invests in cancer and hep. B research; Biogen inks a Parkinson's partnership; Forest names former B&L chief as CEO

AstraZeneca, Sanofi close disappointing quarter

By

The positive way to frame the companies' quarterly results: "less bad," as generics continued to plague their balance sheets.

Cubist buying spree bolsters antibiotic roster

By

The drug maker added biotechs Optimer and Trius to the fold, a bid to dominate in hard-to-treat infections.

BMS to put more sales oomph behind Eliquis, diabetes

BMS to put more sales oomph behind Eliquis, diabetes

By

Sales slid 9% during the second quarter, with generic Avapro and Plavix inflicting financial pain. The company says it is going to invest more to promote Eliquis among HCPs and plans on deploying a wider diabetes sales force.

Higher prices drive Lilly's second-quarter earnings

By

The Indiana drug maker logged a 6% sales increase over the same period last year. Higher prices were responsible for the majority of the growth.

GSK breaks cloud cover with financial results

GSK breaks cloud cover with financial results

By

GlaxoSmithKline second-quarter sales rose 2% over the same period last year. CEO Andrew Witty says it is too early to tally the impact of China's corruption allegations.

Business briefs: Healthcare reform, J&J, Lilly, Quest

The healthcare reform information campaign continues; J&J settles a shareholder lawsuit; Eli Lilly freezes company salaries; and Quest dumps cancer med royalty rights.

Business briefs: Amgen and Wockhardt

Amgen pays $50 million for a cardio collaboration, and Wockhardt gets locked out of the EU.

Roche's son-of-Rituxan scores priority review

By

The FDA's priority review for the Phase III chronic lymphocytic leukemia drug comes on top of Breakthrough Therapy designation, which the agent won in May.

EU backs Remicade biosimilars; anti-TNFs at risk

By

CHMP recommended two Remicade biosimilars for approval. Its nod comes with an added shakeup: the European agency sanctioned the copies for indications beyond RA.

Pill-plus value adds beat brand names in the age of ACOs

By

The effectiveness of new drugs is in decline, says an analysis, and researchers say comparative studies should look beyond efficacy measures.

AstraZeneca buys respiratory specialist Pearl Therapeutics

By

The drug maker eases the burden on its Symbicort franchise by scooping up Pearl for $510 million.

Business briefs: AbbVie, Teva, HIV, Diabetes, iPhone

AbbVie lays off 100 R&D staff; Teva looks to expand Copaxone footprint; researchers crack HIV protein code; monitors may be misleading diabetics and a prototype sensor turns iPhones into virus hunters.

Business briefs: Pfizer, BMS, CMS, Sanofi

Pfizer cuts 136 workers loose in Ireland, BMS is investing in heart failure treatments, CMS has an official new leader, and Sanofi's iBGStar may have a competitor.

Studies show cheaper drugs don't add up to greater use

By

Two studies released show that the story behind lower consumer healthspend isn't about generics improving health.

Business briefs: Baxter; Eli Lilly; CDHPs and Statins

Baxter's Alzheimer's treatment is out of the running; Eli Lilly has upped its layoffs; insured consumers are spending less on healthcare; stains and prostate cancer may have an amicable relationship; doctors aren't screening teens for HIV.

Merck throws more staff behind Januvia; overall sales slid for quarter

By

Sales fell more sharply during the quarter than execs expected, and Merck said it has put more Januvia-only reps behind its diabetes franchise.

Breakup, Xeljanz plans dominate Pfizer earnings call

By

Sales slipped 9% during the quarter, compared to the same period last year, but analysts zeroed in on if and when the company will split and how arthritis pill Xeljanz will tackle Europe.

Forest sees quarterly and annual sales sink

By

Generic Lexapro sapped company sales for the fiscal quarter and year, ended March 31.

Email Newsletters